Expected benefits of cancer immunotherapy
Hope to make cancer a chronic disease – A strong scientific and medical interest for these promising treatments
Emanating from the Memopi® technology, Tedopi® is a patented combination of 10 neo-epitopes, selected from 5 TAA or tumor associated antigens (specific molecules that are present on the surface of tumor cells, and absent or not highly abundant on normal cells). They have been selected from thousands of epitopes and chemically optimized (they are then called “neo-epitopes”) and combined to generate a stronger immune response.
These 10 neo-epitopes are able to generate a specific response from T cytotoxic “killer” cells against malignant cells expressing at least one of these tumor associated antigens. The 5 TAA were selected based on their association with poor clinical prognosis in several cancers. The prognosis is worse when several of the tumor associated antigens are expressed.
The company’s optimized multi-epitope technology and associated clinical applications are considered to be personalised medicine. Indeed, the process involves identifying patients who can most benefit from such a therapy in advance, using a specific marker. Specifically, each of OSE Immunotherapeutics’ Tedopi® epitopes have been selected and optimized to bind strongly with the HLA-A2 receptor, which is the receptor of the T specific response that ensures immunosurveillance.
The presence of this marker is considered as an aggravating risk factor at an advanced stage of cancer. Approximately 45% of the world’s population has these HLA-A2 markers (they are called “HLA-A2+”). Tedopi® is designed specifically for HLA-A2 positive patients.
The Tedopi® neo-epitopes can also be developed for a number of cancers of interest where the same tumour associated antigens are expressed and linked to poor prognosis for patients. Tedopi® will address HLA-A2+ patients who are identified as likely to respond to the treatment, and who also have poor clinical prognosis at advanced stages.
OSE Immunotherapeutics partners with GERCOR, an independent non-profit French network of cancer specialists, to study Tedopi® in locally advanced or metastatic pancreatic cancer. GERCOR is finalizing the design of this Phase 2 trial of maintenance therapy with Tedopi® alone or combined with a PD-1 checkpoint inhibitor versus Folfiri*, in patients with stable disease after 4 months of standard chemotherapy with Folforinox**.
* Folfiri: combination chemotherapy with folinic acid, fluorouracil and irinotecan
** Folfirinox: combination chemotherapy with folinic acid, fluorouracil, irinotecan and oxaliplatin